Neprilysin
(Homo sapiens (Human)) | BDBM300301
(US9593110, 7-8)Show SMILES CCOC[C@H](C[C@@H](Cc1ccc(cc1)-c1cc(Cl)ccc1F)NC(=O)c1coc(n1)C1CC1)C(O)=O Show InChI InChI=1S/C27H28ClFN2O5/c1-2-35-14-19(27(33)34)12-21(30-25(32)24-15-36-26(31-24)18-7-8-18)11-16-3-5-17(6-4-16)22-13-20(28)9-10-23(22)29/h3-6,9-10,13,15,18-19,21H,2,7-8,11-12,14H2,1H3,(H,30,32)(H,33,34)/t19-,21+/m0/s1 | PDB
KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| 2.20 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Theravence Biopharma R&D IP, LLC
US Patent
| Assay Description Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp... |
US Patent US9593110 (2017)
BindingDB Entry DOI: 10.7270/Q2MC9224 |